Catalog No.
DHG93199
Description
Glembatumumab vedotin is an ADC consisting of a GPNMB-directed antibody and Monomethyl auristatin E (MMAE) used for the study of breast cancer and melanoma.
Species reactivity
Human
Clonality
Monoclonal
Target
GPNMB
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Purification
Purified by Ion Exchange Chromatography.
Applications
Research Grade Biosimilar
Form
Liquid
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CR011-vcMMAE, CDX-011
Clone ID
Glembatumumab vedotin
ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer., PMID:36900378
From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds., PMID:36160422
Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic., PMID:35267507
HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin., PMID:35110681
Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)., PMID:34590018
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study., PMID:34016993
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal Melanoma., PMID:32823698
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group., PMID:31586757
Immunotherapy for Uveal Melanoma - Current Knowledge and Perspectives., PMID:31272342
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma., PMID:30690710
Antibody-drug conjugates in triple negative breast cancer., PMID:30175620
Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives., PMID:29439419
Antibodies to watch in 2018., PMID:29300693
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent., PMID:29262642
Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer., PMID:28546082
Antibodies to watch in 2017., PMID:27960628
MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB., PMID:27515299
Emerging targeted therapies for melanoma., PMID:27148822
Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma., PMID:26305408
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer., PMID:25847941
Antibody-drug conjugate for advanced melanoma?, PMID:25602109
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer., PMID:25267761
Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma., PMID:25267741
Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program., PMID:24912408
New developments in metastatic breast cancer: integrating recent data into clinical practice., PMID:24892840
Novel data in metastatic breast cancer., PMID:24637556
Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE)., PMID:24496926
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer., PMID:23874106
The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer., PMID:22229970
Gpnmb/osteoactivin, an attractive target in cancer immunotherapy., PMID:22017590
GPNMB expression in uveal melanoma: a potential for targeted therapy., PMID:20375921
Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer., PMID:20373269
Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer., PMID:20215530
For research use only. Not for human or drug use.
